Last checked at 
LONDON (Alliance News) - Sareum Holdings PLC said Wednesday that it has selected the SDC-1802 molecule from the TYK2 inhibitor programme for further development as potential treatment for certain types of leukaemia, lymphoma and solid tumour.
The drug discovery company said SDC-1802 has shown compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia and B-cell lymphoma.
Sareum intends to progress SDC-1802 into preclinical development and, pending satisfactory progress, into human clinical trials which could begin in 2020.
Shares in the company were trading 6.4% higher at 0.8245 pence each on Wednesday afternoon.
